Search clinical trials for: Merck & Co

Total 477957 results

Merck Sharp & Dohme LLC

Recruiting

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

Ovarian Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
University Hospital, Caen
Merck Sharp & Dohme LLC

Not yet recruiting

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (DOR)

Hiv

France
Diwakar Davar
Merck Sharp & Dohme LLC; Gateway for Cancer Research

Not yet recruiting

Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

PD-1 Refractory Advanced Melanoma

United States
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
University of California, San Francisco
UCSF CAPS-HIV Innovative Grant; UCSF CFAR-ARI HIV Boost Award; ACC/ABC Merck...

Recruiting

Heart Failure Polypill at a Safety Net Hospital

HIV Infections | Heart Failure With Reduced Ejection Fraction

United States
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC; G1 Therapeutics, Inc.

Recruiting

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)

Metastatic Triple-Negative Breast Cancer

United States
Evopoint Biosciences Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Carcinoma | Cervical Cancer | Prostate Cancer | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Other Solid Tumors

China
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Merck Sharp & Dohme LLC

Recruiting

MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Arteriosclerosis | Hypercholesterolaemia

United States, Taiwan, Canada, Israel, New Zealand, Hong Kong, Argentina, Korea, Republic of, Turkey, Australia, Chile, Brazil, Japan, Colombia, China, United Kingdom, Mexico, Peru
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Cancer Prevention Research Institute of Texas

Recruiting

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Oligometastatic Renal Cell Carcinoma

United States
Virginia Commonwealth University
Merck Sharp & Dohme LLC

Recruiting

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip

CMV | Kidney Transplant; Complications

United States
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Tulane University
Merck Sharp & Dohme LLC; Kenema Government Hospital

Not yet recruiting

REVIVE (Response to the Ebola Virus Vaccine)

Ebola Virus Disease

Sierra Leone
Institut Paoli-Calmettes
Merck KGaA, Darmstadt, Germany; National Cancer Institute, France

Not yet recruiting

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX)

Breast Cancer

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; IO Biotech

Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)

Head and Neck Squamous Cell Carcinoma

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Malaria Infection

Kenya, Burkina Faso, Gambia, Zambia
Lin Zhong
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China

Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Recruiting

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell Lymphoma | Fungoides Mycosis Sezary Syndrome

United States
University of Alabama at Birmingham
Merck Sharp & Dohme LLC

Not yet recruiting

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Ovarian Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia
Jennifer Crombie, MD
Merck Sharp & Dohme LLC

Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma Refractory | Primary Mediastinal Large B-Cell Lymphoma Recurrent | Epstein-Barr Virus Positive Diffuse Large...

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, Switzerland, South Africa, Denmark, Argentina, Colombia
Pfizer
Merck Sharpe & Dohme LLC

Recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Italy, Spain, Czechia, Germany, Slovakia, Poland, United Kingdom
Istituti Clinici Scientifici Maugeri SpA
Merck Sharp & Dohme LLC

Not yet recruiting

Pembrolizumab in Locally Advanced Sinonasal Carcinoma (NeoPeSino)

Sinonasal Undifferentiated Carcinoma

Italy
Professor Francois Venter
Merck Sharp & Dohme LLC; Africa Health Research Institute

Recruiting

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (Opti-DOR)

HIV-1-infection

South Africa
University of Alberta
Merck Canada Inc.

Not yet recruiting

Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

Vaccine Response Impaired | Vaccination Failure
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Fundacion GESICA
Merck Sharp & Dohme LLC

Recruiting

A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires

Flavivirus Infections | Dengue

Argentina
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Recruiting

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

Insomnia

United States
University of Zurich
Merck Sharp & Dohme LLC

Recruiting

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (MIPS)

Measles | Rubella | Mumps

Switzerland
Peking University
Merck Sharp & Dohme LLC; Cancer Institute and Hospital, Chinese Academy of... and other collaborators

Recruiting

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Stage IIIA Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIB(N2) Non-small Cell Lung Cancer

China
SOLTI Breast Cancer Research Group
Merck Sharp & Dohme LLC; Pfizer; AstraZeneca; Astellas Pharma Inc; Advanced Accelerator... and other collaborators

Recruiting

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) (HOPE-PROSTATE)

Metastatic Prostate Cancer

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Japan
Kyoto University Hospital
Merck Sharp & Dohme LLC; Astellas Pharma Inc; University of Tsukuba; Kobe City... and other collaborators

Recruiting

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Bladder Cancer

Japan
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; InSightec

Not yet recruiting

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Fatty Liver, Nonalcoholic

Canada, United States, Puerto Rico, Japan, Korea, Republic of, Taiwan, Spain, Israel, Chile, France, Italy, Hungary, Switzerland, Belgium, China, Singapore, Czechia, Portugal, Austria, United Kingdom, Thailand, Hong Kong, Turkey, Colo...
Wellmarker Bio
Merck Sharp & Dohme LLC

Recruiting

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor

Korea, Republic of
Telix Pharmaceuticals (Innovations) Pty Limited
Merck KGaA, Darmstadt, Germany

Recruiting

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Advanced Solid Tumor | Solid Tumor, Adult | Advanced Renal Cell Carcinoma

Australia
Capital Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

App and Body Fat Scale in the Management of Overweight Patients

Schizophrenia | Metabolic Syndrome | Bipolar Disorder
SignalChem Lifesciences Corporation
Merck Sharp & Dohme LLC

Recruiting

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell | Lung Cancer Stage IV

United States, Canada
Zai Lab (Hong Kong), Ltd.
Merck Sharp & Dohme LLC; Zai Biopharmaceutical (Shanghai) Co., Ltd.

Recruiting

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Malignant Solid Tumor

United States, Spain, China
Istituti Clinici Scientifici Maugeri SpA
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in High-risk Thyroid Cancer (NePenThe)

Differentiated Thyroid Cancer

Italy
Merck Sharp & Dohme LLC

Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Switzerland, United States
National Cancer Center, Japan
Merck Sharp & Dohme LLC

Recruiting

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas

Japan

Search clinical trials for: Merck & Co

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations